Mesenchymal Stem Cells in Knee Cartilage Injuries

Use of Mesenchymal Stem Cells for the Repair of Articular Cartilage Disorder of Knee Using Intra-articular Injection of Mesenchymal Cells Alone or Mesenchymal Cells With Platelet Lysate

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02118519

Enrollment

Registered

2014-04-21

Start date

2014-01-31

Completion date

2015-08-31

Last updated

2016-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Articular Cartilage Disorder of Knee, Osteoarthritis, Knee

Keywords

Bone marrow derived Mesenchymal Stem Cells, Knee articular cartilage injury, Chondrogenesis, orthopedics

Brief summary

Induction of autologous repair chondrogenesis to regenerate injured articular cartilage using bone marrow mesenchymal stem cells (MSCs) after in vitro expansion under restricted culturing conditions.

Detailed description

Fourteen patients from both genders, age range 40-68, will be enrolled according to strict inclusion and exclusion criteria, divided into two equal groups based upon receiving autologous MSCs alone, or MSCs supported by platelet lysate through percutaneous injection. The patients are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee. The investigators hypothesize that the two groups will give satisfactory clinical outcomes, but the investigators are looking forward to assessing the best product that will activate chondrogenesis and heal cartilaginous injury.

Interventions

BIOLOGICALAutologous Mesenchymal Stem Cells

Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to 68 Years

Healthy volunteers

Inclusion criteria

* MRI must show moderate/severe articular injury * Serum collagen II must be above the normal value. * Lesion site: Femoral and Tibial condyles or patella * Admission of steroid , NSAID, pain killers must be stopped before 1 month

Exclusion criteria

* Lesion size * PT and PTT not within normal value * Complete blood count ( Hb, PCV, and RBC) not within the normal value * HIV and Hepatitis Antigens (B and C) detection

Design outcomes

Primary

Measure	Time frame
Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells.	12 months

Secondary

Measure	Time frame	Description
Assessment of the articular cartilage healing in osteoarthritic patients through intra articular injection of Autologus Mesenchymal stem cell with/or without supported product.	12 months	For every patient tests would be performed repeated at 6, and 12 months post-injection.

Countries

Jordan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026